A Combination Of Medications More Effective For Older Patients With C-O-P-D

ID

349794

DESCRIPTION
Edited Package
SHOTLIST
INTRO: Chronic obstructive pulmonary disease, or C-O-P-D, is the third leading cause of death worldwide. Medications are the mainstay of C-O-P-D management. A new study examined two different regimens and how these medications might impact older people who have C-O-P-D. Catherine Dolf explains in this week’s JAMA Report. B-ROLL X-ray of patient with COPD, various COPD medications PATIENTS WITH C-O-P-D NOT ONLY HAVE A DIFFICULT TIME BREATHING BUT IF THE DISEASE IS NOT MANAGED WITH EFFECTIVE MEDICATIONS, THERE CAN BE OTHER HEALTH PROBLEMS. SOT/FULL Andrea S. Gershon, M.D., M.Sc., - Sunnybrook Health Sciences Centre Super@:08 Runs:09 (Video covering 2nd part of bite: people walking on street) “It’s not a disease that just affects their lungs. It affects their body they can end up losing a lot of weight and become very weak. They can get osteoporosis and other types of diseases.” B-ROLL Dr. Gershon walking down hall, looking at patient files, walks in room and looks at x-rays, pointing at x-ray DR. ANDREA GERSHON FROM THE SUNNYBROOK HEALTH SCIENCES CENTRE AND CO-AUTHORS STUDIED DATA FROM ALL ACROSS ONTARIO, CANADA, INVOLVING PATIENTS 66 AND OLDER WITH C-O-P-D. PATIENTS WERE NEWLY INTRODUCED TO TWO MEDICATION REGIMENS. THE TWO REGIMENS WERE THEN COMPARED TO FIND OUT WHICH WAS MORE EFFECTIVE AT PREVENTING C-O-P-D RELATED HOSPITALIZATIONS AND DEATH. THE PATIENTS WERE FOLLOWED UNTIL THEY WERE HOSPITALIZED, DIED OR UNTIL THE END OF THE SEVEN YEAR STUDY PERIOD. SOT/FULL Andrea S. Gershon, M.D., M.Sc., - Sunnybrook Health Sciences Centre Super@:42 Runs:13 (Video covering end of bite: COPD medication) “The first group we looked at was people who were on a long-acting beta-agonist, we call them LABA’s for short and we compared them to people who started a long-acting beta-agonist and inhaled corticosteroid.” B-ROLL Graphic showing airways narrowing and inflamed LABA’s HELP OPEN THE NARROWED AIRWAYS AND INHALED CORTICOSTEROIDS WORK TO DECREASE INFLAMMATION IN THOSE AIRWAYS. SOT/FULL Andrea S. Gershon, M.D., M.Sc., - Sunnybrook Health Sciences Centre Super@ 1:04 Runs:10 “If they’re on the combination therapies opposed to the one medication alone they’re actually going to do better, they’re actually going to stay out of hospital and they’re actually going to live longer.” GXF FULL JAMA COVER THE STUDY APPEARS IN JAMA, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. SOT/FULL Andrea S. Gershon, M.D., M.Sc., - Sunnybrook Health Sciences Centre Super@ 1:15 Runs:07 “There were no increase in side effects, specifically pneumonia and osteoporosis that we observed.” B-ROLL Dr. Gershon talking to patient THE STUDY ALSO INCLUDED PEOPLE WHO HAD A DIAGNOSIS OF BOTH ASTHMA AND C-O-P-D. SOT/FULL Andrea S. Gershon, M.D., M.Sc., - Sunnybrook Health Sciences Centre Super@ 1:26 Runs:09 (Video covering end of bite: Dr. Gershon talking with patient) “The incremental benefit of the combination therapy over the LABA alone seemed greater in people with a co-diagnosis of asthma than without asthma.” B-ROLL Various shots of Dr. Gershon listening to patient breathe THE COMBINATION THERAPY WAS ALSO MORE EFFECTIVE WHEN PATIENTS WERE NOT ALREADY TAKING A LONG-ACTING ANTICHOLINERGIC, ANOTHER VERY COMMONLY USED C-O-P-D MEDICATION. SOT/FULL Andrea S. Gershon, M.D., M.Sc., - Sunnybrook Health Sciences Centre Super@1:52 Runs:14 (Video covering 1st of bite: Several COPD medications, Dr. Gershon and patient talking) “I think even as physicians we prefer that patients be on less medication but in this situation, we have an opportunity for patients to have a discussion with their doctors and determine what’s best for them.” B-ROLL Dr. Gershon on camera CATHERINE DOLF, THE JAMA REPORT. TAG: STUDY AUTHORS SAY THESE FINDINGS NEED TO BE CONFIRMED IN OTHER STUDIES AND CLINICAL TRIALS. Please see the complete study for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc. TO CONTACT: Dr. Andrea Gershon call: Deborah Creatura at (647) 406-5996 doi.10.1001/jama.2014.11432 ADDITIONAL SOUNDBITES: Andrea S. Gershon, M.D., M.Sc., - Sunnybrook Health Sciences Centre QUOTE 1 Runs:14 “The data suggests that you know you can take this combination medication and it’s more effective and yet still doesn’t seem to be more dangerous. It seems to be the same safety; you’re not going to get more pneumonias or more osteoporosis.” QUOTE 2 Runs:15 “The combination therapy compared to the LABA alone was even more effective in keeping people out of hospital and keeping them alive when patients weren’t already on a long-acting anticholinergic, another very commonly used COPD medication.”
USAGE RIGHTS/RESTRICTIONS
This media asset is free for editorial broadcast, print, online and radio use. It is restricted for use for other purposes.

Contact

  • JAMA-Archives Media Relations
    Media Relations
    United States
    312-464-5262